<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01248403</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001RDE35T</org_study_id>
    <nct_id>NCT01248403</nct_id>
  </id_info>
  <brief_title>A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy</brief_title>
  <acronym>AIO-STO-0111</acronym>
  <official_title>A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Nordwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Nordwest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adult patients with gastric carcinoma which has progressed after initial treatment with a&#xD;
      fluoropyrimidines-containing regimen will be treated with paclitaxel plus RAD001 or plus&#xD;
      placebo. The hypothesis is that patients with RAD001 have significantly prolonged overall&#xD;
      survival compared to patients who are treated with paclitaxel alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, phase III two-arm multi-center study aiming at estimating&#xD;
      the relative efficacy of the combination of RAD001 and paclitaxel versus that of paclitaxel&#xD;
      alone as second-, third- or fourth-line treatment in terms of hazard ratio of overall&#xD;
      survival in patients with gastric cancer who have relapsed after one treatment regimen&#xD;
      containing a fluoropyrimidine (e.g., 5-FU, S-1, capecitabine and other 5-FU prodrugs or&#xD;
      derivatives). Patients will be randomized in a 1:1 ratio for a total of 240 patients per&#xD;
      treatment arm. Randomization will be stratified according to performance status (0-1 versus&#xD;
      2), prior taxan use (yes vs. no) and treatment line (2nd versus 3rd/4th line).&#xD;
&#xD;
      Study treatment will be continued until progression or intolerable toxicity. Patients will be&#xD;
      seen at baseline/screening, and weekly for paclitaxel administration and safety assessment&#xD;
      until disease progression or discontinuation of trial therapy for other reasons. Radiological&#xD;
      tumor assessment will be performed every second cycle (every 8 weeks) or earlier if&#xD;
      clinically indicated. Post-study follow-up will be completed every 8 weeks for survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2011</start_date>
  <completion_date type="Actual">October 2019</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>best overall response</measure>
    <time_frame>staging every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>staging every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>every week until end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>every 8 weeks</time_frame>
    <description>responders + stable disease ≥12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <condition>Esophagogastric Junction Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.&#xD;
+ Placebo (2 tablets / day) d1-d28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel + RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.&#xD;
+ RAD001 10mg (2 x5 mg tablets / day) d1-d28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.</description>
    <arm_group_label>paclitaxel + RAD001</arm_group_label>
    <arm_group_label>paclitaxel + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>RAD001 10mg (2 x5 mg tablets / day) d1-d28</description>
    <arm_group_label>paclitaxel + RAD001</arm_group_label>
    <other_name>Everolimus</other_name>
    <other_name>Certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ≥ 18 years old&#xD;
&#xD;
          -  Histologically or cytologically confirmed and documented gastric adenocarcinoma.&#xD;
             Adenocarcinomata of the gastro-esophageal junction will be allowed, if they have&#xD;
             advanced disease (inoperable, recurrent or metastatic disease).&#xD;
&#xD;
          -  Documented progressive disease during/after one, two or three prior treatments&#xD;
             containing 5FU and/or its precursors or derivatives in the palliative setting&#xD;
&#xD;
          -  At least one measurable or evaluable lesion by RECIST as determined by Computed&#xD;
             Tomography (CT) Scan or Magnetic Resonance Imaging (MRI)&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2&#xD;
&#xD;
          -  The following laboratory parameters:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 109/L&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 9 g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ 2 x Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Adequate liver function:&#xD;
&#xD;
               -  Total serum calcium (corrected for serum albumin) or ionized calcium ≥ LLN&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test within 7&#xD;
             days of the first administration of study treatments and must be willing to use&#xD;
             adequate methods of contraception during the study and for 3 months after last study&#xD;
             drug administration.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treatment with any anti cancer therapy or treatment with anti cancer therapy ≤&#xD;
             2 weeks prior to study treatment start unless rapidly progressing disease is measured&#xD;
&#xD;
          -  Known hypersensitivity to RAD001 (everolimus) or to its excipients, or to other&#xD;
             rapamycins (e.g. sirolimus, temsirolimus)&#xD;
&#xD;
          -  Known prior history of hypersensitivity to paclitaxel.&#xD;
&#xD;
          -  Paclitaxel refractory disease, which is defined as a disease progression under or&#xD;
             within 12 weeks of last taxan treatment&#xD;
&#xD;
          -  Chronic treatment with steroids (except for oral, topical or local injection) or&#xD;
             another immunosuppressive agent&#xD;
&#xD;
          -  Major surgery ≤ 2 weeks prior to starting study treatment or patients who have not&#xD;
             recovered from such therapy&#xD;
&#xD;
          -  Lack of resolution of all acute toxic effects (excluding alopecia) of prior&#xD;
             chemotherapy, prior radiotherapy, or surgical procedure to National Cancer Institute&#xD;
             (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade &lt;= 1. Note:&#xD;
             Neuropathy due to prior chemotherapy is allowed.&#xD;
&#xD;
          -  Unstable CNS disease&#xD;
&#xD;
               -  Requiring increasing doses of steroids to maintain stable neurological status&#xD;
&#xD;
               -  Deteriorating / changing neurological status&#xD;
&#xD;
          -  Known history of HIV seropositivity (HIV testing is not mandatory) or Hepatitis B or&#xD;
             C.&#xD;
&#xD;
          -  Active, bleeding diathesis or on oral anti-vitamin K medication (except low dose&#xD;
             warfarin, as long as the INR is &lt;= 2.0)&#xD;
&#xD;
          -  Any other severe and/or uncontrolled medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salah-Eddin Al-Batran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Cancer Research (IKF), UCT - University Cancer Center, Frankfurt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2010</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Krankenhaus Nordwest</investigator_affiliation>
    <investigator_full_name>Prof. Dr. S.E. Al-Batran</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>RAD001</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>advanced gastric or esophagogastric junction cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

